New biomarkers for TB could lead to improved vaccines
Posted: 12 April 2016 | Victoria White, Digital Content Producer | No comments yet
A team of scientists have identified new biomarkers for TB which have shown for the first time why immunity from the widely used BCG vaccine is so variable…
A team of scientists led by Oxford University have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Guérin (BCG) vaccine is so variable.
The researchers say the biomarkers will also provide valuable clues to assess whether potential new vaccines could be effective.
TB remains one of the world’s major killer diseases. The only available vaccine, Bacillus Calmette-Guérin (BCG), works well to prevent severe disease in children but is very variable (0% to 80% effective) in how well it protects against lung disease, particularly in countries where TB is most common.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
While BCG is one of the safest and most widely used vaccines worldwide, there is one key issue: It is currently very difficult to determine whether it will work or not. This also makes it really hard to determine if any new vaccines might work.
With a pressing need for a TB vaccine that is more effective than BCG, a research team set out to identify immune correlates that could facilitate TB vaccine development. The team, led by Professor Helen McShane and Dr Helen Fletcher, studied immune responses in infants in South Africa who were taking part in a TB vaccine trial.
Evidence of how BCG might work
The team carried out tests for twenty-two possible factors. One, levels of activated HLA-DR+CD4+ T-cells, was linked to higher TB disease risk. Meanwhile, BCG-specific Interferon-gamma secreting T-cells indicated lower TB risk, with higher levels of these cells directly linked to greater reduction of the risk of TB.
Antibodies to a TB protein, Ag85A, were also identified as a possible correlate. Higher levels of Ag85A antibody were associated with lower TB risk. However, the team cautions that other environmental and disease factors could also cause Ag85A antibody levels to rise and so there may not be a direct link between the antibody and TB risk.
Professor McShane said: “These are useful results which ideally would now be confirmed in further trials. They show that antigen-specific T cells are important in protection against TB, but that activated T cells increase the risk.”
Dr Helen Fletcher from the London School of Hygiene & Tropical Medicine, said: “For the first time we have some evidence of how BCG might work, and also what could block it from working. Although there is still much work to do, these findings may bring us a step closer to developing a more effective vaccine for TB.”
